If you are not at the maximum dose of your medication, a dose increase is a reasonable discussion to have with your provider, particularly if lifestyle factors have been optimized
2021;75:e13731 10.1111/ijcp.13731 REFERENCES 1
The primary endpoint was the time from randomization to first occurrence of a major adverse cardiovascular event (MACE) defined as: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke
These findings have important clinical implications, as they suggest that GLP-1 analogs could be a viable treatment option for patients with MSH, PSW, or other forms of obesity resulting from MC4R deficiencies
Scientific References Obesity: identification, assessment and management (CG189)
We cap our calculator at 15% below maintenance